Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5301739 | 0.99 | SIGMAR1 (0.44) | SIGMAR1SLC6A4LMNAMAPTADRA2C | |
| SCHEMBL2418814 | 0.89 | SIGMAR1 (0.48) | SIGMAR1SLC6A4HTR2ATAAR1SLC6A2 | |
| SCHEMBL5291234 | 0.87 | SIGMAR1 (0.42) | SIGMAR1SLC6A4TAAR1SLC6A2SLC6A3 | |
| SCHEMBL15902430 | 0.85 | TAAR1 (0.57) | SIGMAR1SLC6A4TAAR1SLC6A2SLC6A3 | |
| SCHEMBL113567 | 0.85 | TAAR1 (0.57) | SIGMAR1SLC6A4TAAR1SLC6A2SLC6A3 | |
| SCHEMBL23069122 | 0.82 | SLC6A4 (0.36) | SIGMAR1SLC6A4TAAR1SLC6A2SLC6A3 | |
| SCHEMBL1316541 | 0.79 | TAAR1 (0.55) | SLC6A4HTR2AHTR2BTAAR1SLC6A2 | |
| SCHEMBL1740905 | 0.77 | HTR1B (0.48) | SLC6A4TAAR1SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL4809611 | 0.77 | SLC6A4 (0.41) | SIGMAR1SLC6A4LMNAHTR2AADRA1A | |
| SCHEMBL3293744 | 0.76 | MAOB (0.35) | SIGMAR1SLC6A4ADRA2CHTR2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 529 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | DRESDNER JR KARL P (US) | 2026-04-02 | — | — | US | claimed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | claimed |
| WO-2024178082-A2 | COMPOSITION OF OPIOID RECEPTOR MODULATOR AND MDMA FOR USE THEREOF | FREEDOM BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | claimed |
| US-20240000795-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. | 2024-01-04 | — | — | US | claimed |
| US-20230218570-A1 | Methods and Compositions for Treating Mild Traumatic Brain Injury, Post-Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder | LOBE SCIENCES LTD. (CA) | 2023-07-13 | — | — | US | claimed |
| WO-2021257500-A1 | METHODS AND COMPOSITIONS FOR TREATING MILD TRAUMATIC BRAIN INJURY, POST-TRAUMATIC STRESS DISORDER AND MILD TRAUMATIC BRAIN INJURY WITH POST TRAUMATIC STRESS DISORDER | LOBE SCIENCES LTD. (CA) | 2021-12-23 | — | — | WO | claimed |
| CN-108627595-B | Method for simultaneously detecting 12 alkaline drugs in hair | 司法鉴定科学研究院 | 2021-04-09 | — | — | CN | claimed |
| US-20210055316-A1 | Rapid Method of Forensic Toxicology in Post-Mortem Individuals Using Muscle Tissue Testing | REISINGER AMY J (US) | 2021-02-25 | — | — | US | claimed |
| EP-2884962-B1 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | SMARTEK INT LLC (US) | 2019-05-01 | — | — | EP | claimed |
| US-20180172714-A1 | Rapid and Sensitive Method of Forensic Toxicology in Post-Mortem Subjects Using Oral Fluid Testing | REISINGER AMY J (US) | 2018-06-21 | — | — | US | claimed |
| US-20170189902-A1 | READY-TO-CONSTITUTE ANALYTICAL PLATFORMS FOR CHEMICAL ANALYSES AND QUANTIFICATION | PINPOINT TESTING, LLC (US) | 2017-07-06 | — | — | US | claimed |
| US-9435816-B2 | Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods of their preparation and their use | CHIRON AS (NO) | 2016-09-06 | — | — | US | claimed |
| WO-2016040822-A1 | READY-TO-CONSTITUTE ANALYTICAL PLATFORMS FOR CHEMICAL ANALYSES AND QUANTIFICATION | PINPOINT TESTING, LLC (US) | 2016-03-17 | — | — | WO | claimed |
| WO-2014153099-A2 | METHOD FOR USING EXHALED BREATH TO DETERMINE THE PRESENCE OF DRUG | Pulmonary Analytics (US) | 2014-09-25 | — | — | WO | claimed |
| US-20140288454-A1 | Method For Using Exhaled Breath to Determine the Presence of Drug | Pulmonary Analytics (US) | 2014-09-25 | — | — | US | claimed |
| US-20140227792-A1 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | CHIRON A/S (NO) | 2014-08-14 | — | — | US | claimed |
| EP-1701948-B1 | ASSAY FOR ENTACTOGENS | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2014-03-26 | — | — | EP | claimed |
| WO-2013014287-A2 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | CHIRON AS (NO) | 2013-01-31 | — | — | WO | claimed |
| EP-2551675-A1 | Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods fo their preparation and their use | Chiron AS (NO) | 2013-01-30 | — | — | EP | claimed |
| US-20260138985-A1 | Azepino-Indoles for the Treatment of Neurological and Psychiatric Disorders | TERRAN BIOSCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | TERRAN BIOSCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260125345-A1 | SALTS AND SOLID FORMS OF N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE | TERRAN BIOSCIENCES INC. | 2026-05-07 | — | — | US | disclosed |
| US-12612364-B2 | Salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine hemi-glutarate and hemi-succinate | TERRAN BIOSCIENCES INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4729935-A2 | AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD | F. Hoffmann-La Roche AG (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12600700-B2 | Imidazolium reagent for mass spectrometry | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4720030-A1 | ASYMMETRIC PHENYLALKYLAMINES | Alexander Shulgin Research Institute, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092060-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 2-BROMO-LSD, LSD, ALD-52, AND 1P-LSD | TERRAN BIOSCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260085041-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | TERRAN BIOSCIENCES INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4267951-B1 | AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD | HOFFMANN LA ROCHE (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-20260078090-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | TERRAN BIOSCIENCES INC. | 2026-03-19 | — | — | US | disclosed |
| US-12577222-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | TERRAN BIOSCIENCES INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260072046-A1 | Rapid Method of Forensic Toxicology in Post-Mortem Individuals Using Muscle Tissue Testing | REISINGER AMY J (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4704806-A1 | INJECTABLE PHARMACEUTICAL FORMULATIONS | Cybin IRL Limited (IE) | 2026-03-11 | — | — | EP | disclosed |
| US-12569679-B2 | Treatment delivery system | WearOptimo Pty Ltd (AU) | 2026-03-10 | — | — | US | disclosed |
| US-20260048048-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4153565-B1 | BENZYLPYRIDINIUM REAGENT FOR MASS SPECTROMETRY | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4687880-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | Tactogen Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12534428-B2 | Non-distillative process for manufacturing high purity amphetamines | Pharmapotheca A, Inc. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20260021069-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4673127-A1 | DEUTERATED AND FLUORINATED EMPATHOGENS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-3661500-B1 | USE OF MAVOGLURANT IN THE REDUCTION OF COCAINE USE OR IN PREVENTING RELAPSE INTO COCAINE USE | NOVARTIS AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| EP-3661501-B1 | USE OF MAVOGLURANT IN THE REDUCTION OF ALCOHOL USE OR IN PREVENTING RELAPSE INTO ALCOHOL USE | NOVARTIS AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673430-A2 | PHENYLALKYLAMINE PRODRUGS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20260000641-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (IMDAI) | TERRAN BIOSCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4662205-A1 | DERIVATIVES, IMMUNOGENS, AND ANTIBODIES AND USE OF THE SAME IN DETECTION OF ECSTASY-CLASS COMPOUNDS | Siemens Healthcare Diagnostics, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12484814-B2 | Actuator system | WearOptimo Pty Ltd (AU) | 2025-12-02 | — | — | US | disclosed |
| US-20250347654-A1 | DETECTION OF AN ANALYTE OF INTEREST BY A CHIP BASED NANOESI DETECTION SYSTEM | ROCHE DIAGNOSTICS OPERATIONS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12465578-B2 | Substituted alpha-ethyl phenylalkylamines | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12459912-B2 | Advantageous benzothiophene compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12454515-B2 | 2-aminoindane compounds for mental disorders or enhancement | TACTOGEN INC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250325533-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4623289-A1 | METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST | F. Hoffmann-La Roche AG (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-12424426-B2 | Benzylpyridinium reagent for mass spectrometry | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250283818-A1 | METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-12403150-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2025-09-02 | — | — | US | disclosed |
| US-12404257-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250248969-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI INC (US) | 2025-08-07 | — | — | US | disclosed |
| US-12365661-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4256347-B1 | DETECTION OF AN ANALYTE OF INTEREST BY CROSS SPRAY ESI MASS SPECTROMETRY | HOFFMANN LA ROCHE (CH) | 2025-07-16 | — | — | EP | disclosed |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | Pharmapotheca A, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-12344591-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250205254-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250205198-A1 | METHODS FOR DELIVERY OF PSYCHEDELIC MEDICATIONS BY INHALATION AND SYSTEMS FOR PERFORMING THE METHODS | CYBIN IRL LIMITED (IE) | 2025-06-26 | — | — | US | disclosed |
| US-20250195471-A1 | ASYMMETRIC ALLYL TRYPTAMINES | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250188049-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250186510-A1 | BACTERIAL COMPOSITION FOR USE IN TREATMENT OF SUBSTANCE USE DISORDER | BAR-ILAN UNIVERSITY (IL) | 2025-06-12 | — | — | US | disclosed |
| US-20250179042-A1 | USE OF DEUTERATED EMPATHOGENS AS THERAPEUTIC AGENTS | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-12303564-B2 | Composite chitosan-tannin-active agent compositions and methods of making and using same | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | disclosed |
| EP-4543833-A1 | N-SUBSTITUTED PHENYLALKYLAMINES AND THEIR USE AS THERAPEUTIC AGENTS | Alexander Shulgin Research Institute, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250129037-A1 | FLUORINATED EMPATHOGENS | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250129064-A1 | PRODRUGS OF 2-BROMO-LSD (2-BROMOLYSERGIC ACID DIETHYLAMIDE) | TERRAN BIOSCIENCES INC. | 2025-04-24 | — | — | US | disclosed |
| US-12269818-B2 | Analogs of xanomeline | TERRAN BIOSCIENCES INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250109130-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 2-BROMO-LSD, LSD, ALD-52, AND 1P-LSD | TERRAN BIOSCIENCES INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-12263155-B2 | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use | REMEDI, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| EP-4049017-B1 | APPARATUS AND METHOD FOR DETERMINATION OF BANNED SUBSTANCES | TALLINN UNIV OF TECHNOLOGY (EE) | 2025-03-26 | — | — | EP | disclosed |
| US-12257258-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250091993-A1 | SALTS AND SOLID FORMS OF N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE | TERRAN BIOSCIENCES INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| US-12239632-B2 | Asymmetric allyl tryptamines | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20250066299-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | TERRAN BIOSCIENCES INC (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4221512-B1 | COMPOSITIONS, KITS AND METHODS FOR COLLECTING ANALYTE IN A SALIVA SAMPLE | DECIMA DIAGNOSTICS LLC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12234216-B2 | Isotopologues salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof | TERRAN BIOSCIENCES INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | disclosed |
| US-12221428-B2 | Use of deuterated empathogens as therapeutic agents | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| EP-4499071-A1 | METHODS FOR DELIVERY OF PSYCHEDELIC MEDICATIONS BY INHALATION AND SYSTEMS FOR PERFORMING THE METHODS | Cybin IRL Limited (IE) | 2025-02-05 | — | — | EP | disclosed |
| EP-4499087-A1 | COMBINATION OF NITROUS OXIDE AND 5-HT2A RECEPTOR AGONISTS | Cybin IRL Limited (IE) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034102-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20250034105-A1 | ISOTOPICALLY ENRICHED N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | Pharmapotheca A Inc. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20250025078-A1 | ELECTRODE ARRANGEMENT | WearOptimo Pty Ltd (AU) | 2025-01-23 | — | — | US | disclosed |
| US-12201612-B2 | Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use | NOVARTIS AG (CH) | 2025-01-21 | — | — | US | disclosed |
| US-20250019357-A1 | BENZOFURAN SALT MORPHIC FORMS AND MIXTURES FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2025-01-16 | — | — | US | disclosed |
| US-20250011351-A1 | PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID STATE FORMS THEREOF | TERRAN BIOSCIENCES INC (US) | 2025-01-09 | — | — | US | disclosed |
| US-20250011344-A1 | PRODRUGS AND DERIVATIVES OF PSILOCIN AND USES THEREOF | TERRAN BIOSCIENCES INC (US) | 2025-01-09 | — | — | US | disclosed |
| US-12180176-B2 | Fluorinated empathogens | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-12171771-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240408038-A1 | SUBSTITUTED PHENYLALKYLAMINES | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2024251807-A1 | COMPANION ANIMAL TREATMENTS | CYBIN IRL LIMITED (IE) | 2024-12-12 | — | — | WO | disclosed |
| US-20240409526-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC (US) | 2024-12-12 | — | — | US | disclosed |
| WO-2024243599-A1 | ASYMMETRIC PHENYLALKYLAMINES | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024231331-A1 | INJECTABLE PHARMACEUTICAL FORMULATIONS | CYBIN IRL LIMITED (IE) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024234014-A1 | SUBLINGUAL SPRAY FORMULATIONS OF PSYCHEDELICS | SPIRITUS BIOSCIENCE, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240366655-A1 | COMBINATION DRUG THERAPIES | CYBIN IRL LIMITED (IE) | 2024-11-07 | — | — | US | disclosed |
| US-20240368149-A1 | ANALOGS OF XANOMELINE | TERRAN BIOSCIENCES INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240358783-A1 | METHOD AND SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF A PSYCHEDELIC AGENT | LCT TECHNOLOGIES LLC | 2024-10-31 | — | — | US | disclosed |
| US-20240351993-A1 | Use of Deuterated Empathogens as Therapeutic Agents | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. | 2024-10-24 | — | — | US | disclosed |
| US-20240342126-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | MINDSET PHARMA INC. (CA) | 2024-10-17 | — | — | US | disclosed |
| EP-4444296-A2 | BENZOFURAN SALT MORPHIC FORMS AND MIXTURES FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240335418-A1 | SAFER PSYCHOACTIVE COMPOSITIONS | ARCADIA MEDICINE, INC. | 2024-10-10 | — | — | US | disclosed |
| US-12111260-B2 | Apparatus and method for determination of banned substances | TALLINN UNIVERSITY OF TECHNOLOGY (EE) | 2024-10-08 | — | — | US | disclosed |
| US-20240327371-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024206712-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| EP-4437338-A1 | METHOD FOR DETERMINING AN ANALYTE OF INTEREST BY FREQUENCY DETECTION | F. Hoffmann-La Roche AG (CH) | 2024-10-02 | — | — | EP | disclosed |
| EP-4433466-A2 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240310355-A1 | METHOD FOR DETERMINING AN ANALYTE OF INTEREST BY FREQUENCY DETECTION | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240308999-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2024-09-19 | — | — | US | disclosed |
| EP-4426291-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024182774-A1 | DEUTERATED AND FLUORINATED EMPATHOGENS | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024182807-A2 | PHENYLALKYLAMINE PRODRUGS | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240294488-A1 | ISOTOPOLOGES, SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240294460-A1 | DEUTERATED ANALOGS AND DERIVATIVES OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE AND USES THEREOF | TERRAN BIOSCIENCES INC. | 2024-09-05 | — | — | US | disclosed |
| EP-4423060-A2 | PSYCHOPLASTOGENIC N-SUBSTITUTED INDOLES | Terran Biosciences, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240285608-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-08-29 | — | — | US | disclosed |
| WO-2024178082-A2 | COMPOSITION OF OPIOID RECEPTOR MODULATOR AND MDMA FOR USE THEREOF | FREEDOM BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20240285609-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240286993-A1 | Non-distillative Process for Manufacturing High Purity Amphetamines | Pharmapotheca A, Inc. | 2024-08-29 | — | — | US | disclosed |
| US-20240285607-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240285606-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240285578-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. | 2024-08-29 | — | — | US | disclosed |
| US-20240287016-A1 | Fluorinated Empathogens | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. | 2024-08-29 | — | — | US | disclosed |
| US-20240277665-A1 | ASYMMETRIC ALLYL TRYPTAMINES | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240277691-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-08-22 | — | — | US | disclosed |
| WO-2024167883-A1 | DERIVATIVES, IMMUNOGENS, AND ANTIBODIES AND USE OF THE SAME IN DETECTION OF ECSTASY-CLASS COMPOUNDS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-12043605-B2 | Deuterated empathogens | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4398871-A1 | COMBINATION DRUG THERAPIES | Cybin IRL Limited (IE) | 2024-07-17 | — | — | EP | disclosed |
| CN-118302668-A | Method for determining target analytes by frequency detection | 豪夫迈·罗氏有限公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4392028-A1 | DEUTERATED EMPATHOGENS | Alexander Shulgin Research Institute, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4387952-A1 | DEUTERATED ANALOGS AND DERIVATIVES OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE AND USES THEREOF | Terran Biosciences Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | disclosed |
| US-20240189296-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-06-13 | — | — | US | disclosed |
| US-12006113-B2 | Cannabinoid and alkaloid beverage containers, and associated devices, systems, and methods | Green Sky Creations LLC (US) | 2024-06-11 | — | — | US | disclosed |
| WO-2024115685-A1 | DETECTION OF AN ANALYTE OF INTEREST BY A CHIP BASED NANOESI DETECTION SYSTEM | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-06 | — | — | WO | disclosed |
| CN-118119389-A | Prodrugs and derivatives of des-phosphate nupharicin and uses thereof | 人类生物科学股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2024110422-A1 | METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST | F. HOFFMANN-LA ROCHE AG (CH) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024108195-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4366731-A2 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDLICS AND USES THEREOF | Terran Biosciences, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4366729-A2 | SAFER PSYCHOACTIVE COMPOSITIONS | Arcadia Medicine, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024091523-A1 | CONFORMATIONALLY RESTRICTED PHENETHYLAMINE ANALOGS | 2A BIOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| CN-117956991-A | N, N-dimethyltryptamine and related hallucinogens and uses thereof | 人类生物科学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240122913-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240122895-A1 | ENTACTOGEN-ASSISTED THERAPY FOR ALCOHOL USE DISORDER AND ADDICTION-RELATED CONDITIONS AND COMORBIDITIES | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2024-04-18 | — | — | US | disclosed |
| US-20240122914-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240124411-A1 | Deuterated Empathogens | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11958821-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | TERRAN BIOSCIENCES INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240116870-A1 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | TERRAN BIOSCIENCES INC. | 2024-04-11 | — | — | US | disclosed |
| US-20240108640-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-04-04 | — | — | US | disclosed |
| US-11945832-B2 | Psilocybin and O-acetylpsilocin, salts and solid state forms thereof | TERRAN BIOSCIENCES INC. | 2024-04-02 | — | — | US | disclosed |
| CN-117761188-A | Method for detecting addiction and toxic and harmful substances in tea | 梧州市天誉茶业有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20240082274-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | TURTLE BEAR HOLDINGS, LLC | 2024-03-14 | — | — | US | disclosed |
| US-20240083864-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC | 2024-03-14 | — | — | US | disclosed |
| EP-4333838-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | Turtle Bear Holdings, LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024044756-A1 | DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF PSYCHEDELIC THERAPEUTICS | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11911401-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11905295-B2 | Solid forms of tabernanthalog monofumarate salt for treating neurological disorders and/or psychiatric disorders | TERRAN BIOSCIENCES INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-11896587-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLP (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313007-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | Lyfe CHNG, LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240034718-A1 | SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE | TERRAN BIOSCIENCES INC. | 2024-02-01 | — | — | US | disclosed |
| US-11878001-B2 | Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use | NOVARTIS AG (CH) | 2024-01-23 | — | — | US | disclosed |
| US-20240010663-A1 | PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID STATE FORMS THEREOF | TERRAN BIOSCIENCES INC. | 2024-01-11 | — | — | US | disclosed |
| US-11866408-B2 | N,N-dimethyltryptamine and related psychedelics and uses thereof | TERRAN BIOSCIENCES INC. (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024006226-A1 | N-SUBSTITUTED PHENYLALKYLAMINES AND THEIR USE AS THERAPEUTIC AGENTS | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20240000795-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. | 2024-01-04 | — | — | US | disclosed |
| US-20240002337-A1 | SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE | TERRAN BIOSCIENCES INC (US) | 2024-01-04 | — | — | US | disclosed |
| US-11850254-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-11851452-B2 | Psilocybin and O-acetylpsilocin, salts and solid state forms thereof | TERRAN BIOSCIENCES INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230407369-A1 | COMPOSITIONS, KITS AND METHODS FOR COLLECTING ANALYTE IN A SALIVA SAMPLE | Decima Diagnostics, LLC | 2023-12-21 | — | — | US | disclosed |
| US-20230346811-A1 | Novel Formulations of Psilocybin And Psilocin Compounds as Serotonin Agonists in Combination With 3,4 Methylenedioxymethamphetamine (MDMA) | Altrartis Therapeutics Inc. | 2023-11-02 | — | — | US | disclosed |
| EP-4267951-A1 | AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD | F. Hoffmann-La Roche AG (CH) | 2023-11-01 | — | — | EP | disclosed |
| US-20230333113-A1 | DETECTION OF AN ANALYTE OF INTEREST BY NANOESI MASS SPECTROMETRY | ROCHE DIAGNOSTICS GMBH (DE) | 2023-10-19 | — | — | US | disclosed |
| US-20230324398-A1 | REAGENT FOR MASS SPECTROMETRY | ROCHE DIAGNOSTICS GMBH (DE) | 2023-10-12 | — | — | US | disclosed |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | CHEMAPOTHECA, LLC (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023186963-A1 | COMBINATION OF NITROUS OXIDE AND 5-HT2A RECEPTOR AGONISTS | CYBIN IRL LIMITED (IE) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023186867-A1 | METHODS FOR DELIVERY OF PSYCHEDELIC MEDICATIONS BY INHALATION AND SYSTEMS FOR PERFORMING THE METHODS | CYBIN IRL LIMITED (IE) | 2023-10-05 | — | — | WO | disclosed |
| US-11767305-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2023-09-26 | — | — | US | disclosed |
| WO-2023170687-A1 | BACTERIAL COMPOSITION FOR USE IN TREATMENT OF SUBSTANCE USE DISORDER | BAR-ILAN UNIVERSITY (IL) | 2023-09-14 | — | — | WO | disclosed |
| US-20230286710-A1 | CANNABINOID AND ALKALOID BEVERAGE CONTAINERS, AND ASSOCIATED DEVICES, SYSTEMS, AND METHODS | Green Sky Creations LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230279017-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | TERRAN BIOSCIENCES INC. | 2023-09-07 | — | — | US | disclosed |
| CN-116710783-A | Detection of target analytes by cross-spray ESI mass spectrometry | 豪夫迈·罗氏有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20230270720-A1 | MAVOGLURANT, A MGLUR5 ANTAGONIST, FOR USE IN THE TREATMENT IN THE REDUCTION OF OPIOID USE | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| EP-4232824-A1 | DETECTION OF AN ANALYTE OF INTEREST BY NANOESI MASS SPECTROMETRY | F. Hoffmann-La Roche AG (CH) | 2023-08-30 | — | — | EP | disclosed |
| US-20230266283-A1 | METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| CN-116615649-A | Automated clinical diagnostic system and method | 豪夫迈·罗氏有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20230257385-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | TERRAN BIOSCIENCES INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-08-17 | — | — | US | disclosed |
| EP-4221512-A1 | COMPOSITIONS, KITS AND METHODS FOR COLLECTING ANALYTE IN A SALIVA SAMPLE | Decima Diagnostics, LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | Pharmapotheca A, Inc. (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2023147424-A1 | SALTS AND SOLID FORMS OF N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)- N-METHYLETHAN-1-AMINE | TERRAN BIOSCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023141636-A1 | PRODRUGS OF 2-BROMO-LSD (2-BROMOLYSERGIC ACID DIETHYLAMIDE) | TERRAN BIOSCIENCES INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| EP-4214192-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | Tactogen Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230227422-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2023137446-A1 | PRODRUGS OF 3,4-METHYLENEDIOXY- N-ETHYL-AMPHETAMINE (MDEA) AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137446-A1 | PRODRUGS OF 3,4-METHYLENEDIOXY- N-ETHYL-AMPHETAMINE (MDEA) AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230218570-A1 | Methods and Compositions for Treating Mild Traumatic Brain Injury, Post-Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder | LOBE SCIENCES LTD. (CA) | 2023-07-13 | — | — | US | disclosed |
| WO-2023133477-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | TERRAN BIOSCIENCES, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230210872-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212119-A1 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | TERRAN BIOSCIENCES INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023129976-A1 | SALT AND SOLID FORMS OF KETANSERIN | TERRAN BIOSCIENCES, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230202998-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC (US) | 2023-06-29 | — | — | US | disclosed |
| CN-116323568-A | Detection of target analytes by nanoESI mass spectrometry | 豪夫迈·罗氏有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230192642-A1 | ISOTOPOLOGUES SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023107653-A2 | BENZOFURAN SALT MORPHIC FORMS AND MIXTURES FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107966-A1 | SALT AND SOLID FORMS OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND ANALOGS | TERRAN BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230181521-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (MDAI) | TERRAN BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2023108172-A2 | ANALOGS OF 4-SUBSTITUTED-2,5-DIMETHOXYAMPHETAMINE | TERRAN BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230183199-A1 | 2-AMINOINDANE COMPOUNDS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC. (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2023107965-A1 | SALT AND SOLID FORMS OF 1-(2,5-DIMETHOXY-4-METHYLPHENYL)-2-AMINOPROPANE (DOM), 2,5-DIMETHOXY-4-IODOAMPHETAMINE (DOI), 2,5-DIMETHOXY-4-BROMOAMPHETAMINE (DOB), AND 2,5-DIMETHOXY-4-CHLOROAMPHETAMINE (DOC) | TERRAN BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023108174-A1 | ANALOGS OF 6-METHOXY- N, N-DIMETHYLTRYPTAMINE | TERRAN BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-4192447-A1 | 2-AMINOINDANE COMPOUNDS FOR MENTAL DISORDERS OR ENHANCEMENT | Tactogen Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4193381-A1 | METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST | F. Hoffmann-La Roche AG (CH) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023094385-A1 | METHOD FOR DETERMINING AN ANALYTE OF INTEREST BY FREQUENCY DETECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2023-06-01 | — | — | WO | disclosed |
| US-11660305-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023091974-A2 | SALT AND SOLID FORMS OF (R)-1-(5-METHOXY-1 H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE | TERRAN BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230159544-A1 | AZEPINO-INDOLES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | TERRAN BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023092045-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | TERRAN BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023092044-A2 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230160904-A1 | REAGENT FOR MASS SPECTROMETRY | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4181918-A2 | MAVOGLURANT, A MGLUR5 ANTAGONIST, FOR USE IN THE TREATMENT IN THE REDUCTION OF OPIOID USE | Novartis AG (CH) | 2023-05-24 | — | — | EP | disclosed |
| WO-2023087034-A1 | SALTS AND SOLID FORMS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230150963-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150965-A1 | ISOTOPICALLY ENRICHED N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150920-A1 | SALTS AND SOLID FORMS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150966-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151036-A1 | PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID STATE FORMS THEREOF | TERRAN BIOSCIENCES INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2023081403-A1 | ISOTOPOLOGES, SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081306-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081899-A1 | ISOTOPICALLY ENRICHED N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081897-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-4175638-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | Tactogen Inc. (US) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023077127-A2 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230127289-A1 | BENZYLPYRIDINIUM REAGENT FOR MASS SPECTROMETRY | ROCHE DIAGNOSTICS GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| CN-115997270-A | Method for determining at least one analyte of interest | 豪夫迈·罗氏有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4161503-A2 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | Tactogen Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11622971-B2 | — | — | 2023-04-11 | — | — | US | disclosed |
| US-20230104200-A1 | IMIDAZOLIUM REAGENT FOR MASS SPECTROMETRY | ROCHE DIAGNOSTICS GMBH (DE) | 2023-04-06 | — | — | US | disclosed |
| EP-4153572-A1 | IMIDAZOLIUM REAGENT FOR MASS SPECTROMETRY | F. Hoffmann-La Roche AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| EP-4153565-A1 | BENZYLPYRIDINIUM REAGENT FOR MASS SPECTROMETRY | F. Hoffmann-La Roche AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| EP-4154010-A1 | REAGENT FOR MASS SPECTROMETRY | F. Hoffmann-La Roche AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| EP-4154009-A1 | REAGENT FOR MASS SPECTROMETRY | F. Hoffmann-La Roche AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| WO-2023036473-A1 | COMBINATION DRUG THERAPIES | CYBIN IRL LIMITED (IE) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023034645-A2 | ASYMMETRIC ALLYL TRYPTAMINES | ALEXANDER SHULGIN RESEARCH INSTITUTE (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023028091-A1 | DEUTERATED EMPATHOGENS | ALEXANDER SHULGIN RESEARCH INSTITUTE (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023019298-A1 | IMPROVED METHOD OF SYNTHESIS OF 1-(3',4'-METHYLENE DIOXYPHENYL)-2-(METHYLAMINO) PROPANE (MDMA) | MIND MEDICINE AUSTRALIA LIMITED (AU) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023351-A1 | DEUTERATED ANALOGS AND DERIVATIVES OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20230053962-A1 | ANALYTE MEASUREMENT SYSTEM | WearOptimo Pty Ltd (AU) | 2023-02-23 | — | — | US | disclosed |
| CN-115667220-A | Benzyl pyridinium reagent for mass spectrum | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115667223-A | Imidazolium reagents for mass spectrometry | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115667933-A | Reagent for mass spectrometry | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2023283386-A2 | SAFER PSYCHOACTIVE COMPOSITIONS | ARCADIA MEDICINE, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023283364-A2 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDLICS AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-11548703-B1 | Cannabinoid and alkaloid beverage containers, and associated devices, systems, and methods | Green Sky Creations LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220370483-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | TURTLE BEAR HOLDINGS, LLC | 2022-11-24 | — | — | US | disclosed |
| WO-2022235587-A1 | LIPID PRODRUGS OF TRYPTAMINE AND PHENETHYLAMINE PSYCHEDELICS AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022236130-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | TURTLE BEAR HOLDINGS, LLC (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20220346679-A1 | ANALYTE MEASUREMENT SYSTEM | WearOptimo Pty Ltd (AU) | 2022-11-03 | — | — | US | disclosed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022212789-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | MYCRODOSE THERAPEUTICS INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20220296720-A1 | COMPOSITE CHITOSAN-TANNIN-ACTIVE AGENT COMPOSITIONS AND METHODS OF MAKING AND USING SAME | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-09-22 | — | — | US | disclosed |
| EP-4049017-A2 | APPARATUS AND METHOD FOR DETERMINATION OF BANNED SUBSTANCES | Tallinn University of Technology (EE) | 2022-08-31 | — | — | EP | disclosed |
| WO-2022150525-A1 | MDMA IN THE TREATMENT OF ALCOHOL USE DISORDER | AWAKN LIFE SCIENCES (CA) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022136286-A1 | AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-30 | — | — | WO | disclosed |
| US-20220178825-A1 | APPARATUS AND METHOD FOR DETERMINATION OF BANNED SUBSTANCES | TALLINN UNIVERSITY OF TECHNOLOGY (EE) | 2022-06-09 | — | — | US | disclosed |
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3994458-A1 | ARYLALKYLAMINE, PYRROLE, INDOLE AND OPIATE DERIVATIVE CONCENTRATION DETERMINATION METHOD AND TEST KIT USING SAID METHOD | Blei, Felix (DE) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022084362-A1 | DETECTION OF AN ANALYTE OF INTEREST BY NANOESI MASS SPECTROMETRY | F. HOFFMANN-LA ROCHE AG (CH) | 2022-04-28 | — | — | WO | disclosed |
| US-20220125809-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | STAMETS PAUL EDWARD (US) | 2022-04-28 | — | — | US | disclosed |
| WO-2022034018-A1 | METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST | F. HOFFMANN-LA ROCHE AG (CH) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022013809-A2 | USE OF mGluR5 ANTAGONISTS | NOVARTIS AG (CH) | 2022-01-20 | — | — | WO | disclosed |
| WO-2022010937-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20210402182-A1 | TREATMENT DELIVERY SYSTEM | WearOptimo Pty Ltd (AU) | 2021-12-30 | — | — | US | disclosed |
| WO-2021257500-A1 | METHODS AND COMPOSITIONS FOR TREATING MILD TRAUMATIC BRAIN INJURY, POST-TRAUMATIC STRESS DISORDER AND MILD TRAUMATIC BRAIN INJURY WITH POST TRAUMATIC STRESS DISORDER | LOBE SCIENCES LTD. (CA) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021252538-A2 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210386373-A1 | ANALYTE DETECTION SYSTEM | WearOptimo Pty Ltd (AU) | 2021-12-16 | — | — | US | disclosed |
| WO-2021234003-A1 | BENZYLPYRIDINIUM REAGENT FOR MASS SPECTROMETRY | F. HOFFMANN-LA ROCHE AG (CH) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021233997-A1 | REAGENT FOR MASS SPECTROMETRY | F. HOFFMANN-LA ROCHE AG (CH) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021234002-A1 | REAGENT FOR MASS SPECTROMETRY | F. HOFFMANN-LA ROCHE AG (CH) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021234004-A1 | IMIDAZOLIUM REAGENT FOR MASS SPECTROMETRY | F. HOFFMANN-LA ROCHE AG (CH) | 2021-11-25 | — | — | WO | disclosed |
| US-20210338158-A1 | MEASUREMENT SYSTEM | WearOptimo Pty Ltd (AU) | 2021-11-04 | — | — | US | disclosed |
| US-20210321916-A1 | ACTUATOR SYSTEM | WearOptimo Pty Ltd (AU) | 2021-10-21 | — | — | US | disclosed |
| CN-112156497-B | Liquid-liquid electro-extraction device for enriching trace analytes and capable of realizing two phases of non-aqueous mutual solution and application of liquid-liquid electro-extraction device | 南方医科大学 | 2021-10-12 | — | — | CN | disclosed |
| US-11123310-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | PHARMAPOTHECA, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210251976-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3860449-A1 | ELECTRODE ARRANGEMENT | Wearoptimo Pty Ltd (AU) | 2021-08-11 | — | — | EP | disclosed |
| US-11045454-B2 | Methods of treating food allergy conditions | Palo Alto Investors LP (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2021101926-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | STAMETS PAUL EDWARD (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-05-20 | — | — | US | disclosed |
| CN-108627595-B | Method for simultaneously detecting 12 alkaline drugs in hair | 司法鉴定科学研究院 | 2021-04-09 | — | — | CN | disclosed |
| WO-2021062475-A1 | ANALYTE MEASUREMENT SYSTEM | WearOptimo Pty Ltd (AU) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021062476-A1 | ANALYTE MEASUREMENT SYSTEM | WearOptimo Pty Ltd (AU) | 2021-04-08 | — | — | WO | disclosed |
| US-20210093609-A1 | USE OF MAVOGLURANT IN THE REDUCTION OF COCAINE USE OR IN PREVENTING RELAPSE INTO COCAINE USE | NOVARTIS AG (CH) | 2021-04-01 | — | — | US | disclosed |
| CN-112492881-A | Reagent for mass spectrometry | 豪夫迈·罗氏有限公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-112492882-A | Reagent for mass spectrometry | 豪夫迈·罗氏有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-03-11 | — | — | US | disclosed |
| CN-112449636-A | Reagent for mass spectrometry | 豪夫迈·罗氏有限公司 | 2021-03-05 | — | — | CN | disclosed |
| WO-2021038112-A2 | APPARATUS AND METHOD FOR DETERMINATION OF BANNED SUBSTANCES | TALLINN UNIVERSITY OF TECHNOLOGY (EE) | 2021-03-04 | — | — | WO | disclosed |
| US-20210055316-A1 | Rapid Method of Forensic Toxicology in Post-Mortem Individuals Using Muscle Tissue Testing | REISINGER AMY J (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210046014-A1 | PHARMACEUTICAL ABUSE DETERRENT COMPOSITION CONSTRUCTED IN MORE THAN ONE STRENGTHS | Patel, Jayendrakumar Dasharathlal (IN) | 2021-02-18 | — | — | US | disclosed |
| US-20210030699-A1 | Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms | PHARMAPOTHECA, LLC (US) | 2021-02-04 | — | — | US | disclosed |
| WO-2021000997-A1 | ARYLALKYLAMINE, PYRROLE, INDOLE AND OPIATE DERIVATIVE CONCENTRATION DETERMINATION METHOD AND TEST KIT USING SAID METHOD | BLEI FELIX (DE) | 2021-01-07 | — | — | WO | disclosed |
| CN-112156497-A | Liquid-liquid electro-extraction device for enriching trace analytes and capable of realizing two phases of non-aqueous mutual solution and application of liquid-liquid electro-extraction device | 南方医科大学 | 2021-01-01 | — | — | CN | disclosed |
| US-20200368169-A1 | ABUSE-DETERRENT COMPOSITIONS | PATHEON SOFTGELS INC (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200352883-A1 | METHODS OF TREATMENT USING AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC (US) | 2020-11-12 | — | — | US | disclosed |
| US-10772842-B2 | Abuse-deterrent opioids | PATHEON SOFTGELS INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10772841-B2 | Opioid abuse-deterrent controlled release formulations | PATHEON SOFTGELS INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10753952-B2 | Rapid and sensitive method of forensic toxicology in post-mortem subjects and in live and post-mortem animals using oral fluid testing | REISINGER AMY J (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200237721-A1 | USE OF MAVOGLURANT IN THE REDUCTION OF ALCOHOL USE OR IN PREVENTING RELAPSE INTO ALCOHOL USE | NOVARTIS AG (CH) | 2020-07-30 | — | — | US | disclosed |
| US-20200230128-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2020-07-23 | — | — | US | disclosed |
| US-20200206218-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2020-07-02 | — | — | US | disclosed |
| US-20200179349-A1 | Methods of Treating Food Allergy Conditions | Palo Alto Investors LP | 2020-06-11 | — | — | US | disclosed |
| EP-3661500-A1 | USE OF MAVOGLURANT IN THE REDUCTION OF COCAINE USE OR IN PREVENTING RELAPSE INTO COCAINE USE | Novartis AG (CH) | 2020-06-10 | — | — | EP | disclosed |
| EP-3661501-A1 | USE OF MAVOGLURANT IN THE REDUCTION OF ALCOHOL USE OR IN PREVENTING RELAPSE INTO ALCOHOL USE | Novartis AG (CH) | 2020-06-10 | — | — | EP | disclosed |
| CN-105938135-B | Analysis device comprising a bubble formation mechanism | SPD瑞士精确诊断有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-20200129502-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2020-04-30 | — | — | US | disclosed |
| WO-2020069567-A1 | ELECTRODE ARRANGEMENT | WearOptimo Pty Ltd (AU) | 2020-04-09 | — | — | WO | disclosed |
| US-10478429-B2 | Abuse deterrent dosage forms | Patheon Softgels, Inc. (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190250178-A1 | Rapid and Sensitive Method of Forensic Toxicology in Post-Mortem Subjects and in Live and Post-Mortem Animals Using Oral Fluid Testing | REISINGER AMY J (US) | 2019-08-15 | — | — | US | disclosed |
| EP-3365674-B1 | USE OF FUNCTIONALIZED OCTAHEDRAL OLIGOSILSESQUIOXANES AS SENSITIVE MATERIALS IN CHEMICAL SENSORS FOR DETECTING THE PRESENCE OF NARCOTICS IN A GAS MEDIUM | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2019-08-14 | — | — | EP | disclosed |
| US-10335405-B1 | Non-burst releasing pharmaceutical composition | Patheon Softgels, Inc. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3478363-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS | Chemapotheca LLC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10267811-B2 | Rapid and sensitive method of forensic toxicology in post-mortem subjects using oral fluid testing | REISINGER AMY J (US) | 2019-04-23 | — | — | US | disclosed |
| WO-2019064082-A2 | PHARMACEUTICAL ABUSE DETERRENT COMPOSITION CONSTRUCTED IN MORE THAN ONE STRENGTHS | PATEL JAYENDRAKUMAR DASHARATHLAL (IN) | 2019-04-04 | — | — | WO | disclosed |
| US-10226432-B2 | Enteric soft capsule compositions | PATHEON SOFTGELS INC. (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2019025932-A1 | USE OF MAVOGLURANT IN THE REDUCTION OF ALCOHOL USE OR IN PREVENTING RELAPSE INTO ALCOHOL USE | NOVARTIS AG (CH) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019025931-A1 | USE OF MAVOGLURANT IN THE REDUCTION OF COCAINE USE OR IN PREVENTING RELAPSE INTO COCAINE USE | NOVARTIS AG (CH) | 2019-02-07 | — | — | WO | disclosed |
| US-10182992-B2 | Abuse-deterrent controlled release formulations | PATHEON SOFTGELS INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180344728-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2018-12-06 | — | — | US | disclosed |
| US-20180333360-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING PAIN | CHARLESTON LABORATORIES, INC. | 2018-11-22 | — | — | US | disclosed |
| US-20180325892-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2018-11-15 | — | — | US | disclosed |
| US-10105321-B2 | Pharmaceutical compositions resistant to abuse | EGALET LTD. (GB) | 2018-10-23 | — | — | US | disclosed |
| US-10064856-B2 | Pharmaceutical compositions | LOCAL PHARMA, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20180243241-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC | 2018-08-30 | — | — | US | disclosed |
| US-10016368-B2 | Pharmaceutical compositions for treating or preventing pain | LOCL PHARMA, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180172714-A1 | Rapid and Sensitive Method of Forensic Toxicology in Post-Mortem Subjects Using Oral Fluid Testing | REISINGER AMY J (US) | 2018-06-21 | — | — | US | disclosed |
| EP-3311667-A1 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-3005400-B1 | IMPROVED DATA QUALITY AFTER DEMULTIPLEXING OF OVERLAPPING ACQUISITION WINDOWS | DH TECHNOLOGIES DEV PTE LTD (SG) | 2018-04-18 | — | — | EP | disclosed |
| EP-1701949-B1 | ASSAY FOR ENTACTOGENS | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180071278-A1 | ANTI-OVERINGESTION DOSAGE FORMS | PATHEON SOFTGELS INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180064817-A1 | Tamper Resistant Pharmaceutical Composition | Patel, Jayendrakumar Dasharathlal (IN) | 2018-03-08 | — | — | US | disclosed |
| US-20180055837-A1 | ABUSE DETERRENT DOSAGE FORMS | PATHEON SOFTGELS INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180015046-A1 | ENTERIC SOFT CAPSULE COMPOSITIONS | PATHEON SOFTGELS INC (US) | 2018-01-18 | — | — | US | disclosed |
| US-9855264-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170360772-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170348304-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170348305-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170348303-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170333354-A9 | ABUSE DETERRENT PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED RELEASE | EGALET LTD. (GB) | 2017-11-23 | — | — | US | disclosed |
| US-9818590-B2 | Data quality after demultiplexing of overlapped acquisition windows in tandem mass spectrometry | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2017-11-14 | — | — | US | disclosed |
| WO-2017189947-A1 | PHARMACEUTICAL DOSAGE FORMS | ASCENT PHARMACEUTICALS, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2017182861-A1 | TAMPER RESISTANT PHARMACEUTICAL COMPOSITION | PATEL JAYENDRAKUMAR DASHARATHLAL (IN) | 2017-10-26 | — | — | WO | disclosed |
| US-20170304150-A1 | STABLE PACKAGING SYSTEM FOR MOISTURE AND OXYGEN SENSITIVE PHARMACEUTICAL DOSAGE FORMS | ASCENT PHARMA INC (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2017184584-A1 | STABLE PACKAGING SYSTEM FOR MOISTURE AND OXYGEN SENSITIVE PHARMACEUTICAL DOSAGE FORMS | ASCENT PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-9789105-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789104-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2451274-B1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9775837-B2 | Pharmaceutical compositions | CHARLESTON LABORATORIES, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9775814-B2 | Enteric soft capsule compositions | PATHEON SOFTGELS INC. (US) | 2017-10-03 | — | — | US | disclosed |
| WO-2017147375-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170189902-A1 | READY-TO-CONSTITUTE ANALYTICAL PLATFORMS FOR CHEMICAL ANALYSES AND QUANTIFICATION | PINPOINT TESTING, LLC (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170181974-A1 | ABUSE DETERRENT PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED RELEASE | EGALET LTD. (GB) | 2017-06-29 | — | — | US | disclosed |
| EP-3184105-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | Egalet Ltd. (GB) | 2017-06-28 | — | — | EP | disclosed |
| US-20170157055-A1 | PHARMACEUTICAL ABUSE DETERRENT COMPOSITION | Patel, Jayendrakumar Dasharathlal (IN) | 2017-06-08 | — | — | US | disclosed |
| WO-2017066488-A1 | TREATING PAIN USING A COMPOSITION COMPRISING AN OPIOID AND AN ANTIEMETIC | CHARLESTON LABORATORIES, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20170100341-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | EGALET LTD. (GB) | 2017-04-13 | — | — | US | disclosed |
| US-20170049704-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING PAIN | CHARLESTON LABORATORIES, INC. | 2017-02-23 | — | — | US | disclosed |
| CN-106413717-A | Pharmaceutical compositions | 查尔斯顿实验室公司 | 2017-02-15 | — | — | CN | disclosed |
| US-9549899-B2 | Abuse deterrent pharmaceutical compositions for controlled release | EGALET LTD. (GB) | 2017-01-24 | — | — | US | disclosed |
| US-20160375015-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2016-12-29 | — | — | US | disclosed |
| EP-2240022-B1 | Bilayered tablets comprising oxycodone and promethazine | CHARLESTON LABORATORIES INC (US) | 2016-12-28 | — | — | EP | disclosed |
| US-9526704-B2 | Pharmaceutical compositions for treating or preventing pain | LOCL PHARMA, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9498444-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9498446-B2 | Pharmaceutical compositions resistant to abuse | EGALET LTD. (GB) | 2016-11-22 | — | — | US | disclosed |
| EP-3090743-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING HEADACHE AND ELIMINATING NAUSEA | Charleston Laboratories, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160317447-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING PAIN | CHARLESTON LABORATORIES, INC. | 2016-11-03 | — | — | US | disclosed |
| EP-2393487-B1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | EGALET LTD (GB) | 2016-11-02 | — | — | EP | disclosed |
| US-9433625-B2 | Pharmaceutical compositions for treating or preventing pain | LOCL PHARMA, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9435816-B2 | Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods of their preparation and their use | CHIRON AS (NO) | 2016-09-06 | — | — | US | disclosed |
| WO-2016111731-A1 | ABUSE-DETERRENT OPIOIDS | BANNER LIFE SCIENCES LLC (US) | 2016-07-14 | — | — | WO | disclosed |
| US-20160199368-A1 | ABUSE-DETERRENT OPIOIDS | PATHEON SOFTGELS INC. | 2016-07-14 | — | — | US | disclosed |
| US-9387177-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9358295-B2 | Immediate release composition resistant to abuse by intake of alcohol | EGALET LTD. (GB) | 2016-06-07 | — | — | US | disclosed |
| US-9347961-B2 | Test kit for the quantitative determination of narcotic drugs | CHIRON AS (NO) | 2016-05-24 | — | — | US | disclosed |
| US-20160106755-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2016-04-21 | — | — | US | disclosed |
| EP-3005400-A1 | IMPROVED DATA QUALITY AFTER DEMULTIPLEXING OF OVERLAPPING ACQUISITION WINDOWS | DH Technologies Development PTE. Ltd. (SG) | 2016-04-13 | — | — | EP | disclosed |
| WO-2016046842-A1 | PHARMACEUTICAL ABUSE DETERRENT COMPOSITION | PATEL JAYENDRAKUMAR DASHARATHLAL (IN) | 2016-03-31 | — | — | WO | disclosed |
| US-20160086783-A1 | Improved Data Quality after Demultiplexing of Overlapped Acquisition Windows | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2016-03-24 | — | — | US | disclosed |
| WO-2016040822-A1 | READY-TO-CONSTITUTE ANALYTICAL PLATFORMS FOR CHEMICAL ANALYSES AND QUANTIFICATION | PINPOINT TESTING, LLC (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20160074332-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | EGALET LTD. (GB) | 2016-03-17 | — | — | US | disclosed |
| US-20160051474-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2016-02-25 | — | — | US | disclosed |
| US-9226901-B2 | Pharmaceutical compositions | LOCL PHARMA, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150366815-A1 | ENTERIC SOFT CAPSULE COMPOSITIONS | WXM LLC | 2015-12-24 | — | — | US | disclosed |
| WO-2015195989-A1 | ENTERIC SOFT CAPSULE COMPOSITIONS | BANNER LIFE SCIENCES LLC (US) | 2015-12-23 | — | — | WO | disclosed |
| US-9198867-B2 | Pharmaceutical compositions | CHARLESTON LABORATORIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150320685-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150313997-A1 | IMMEDIATE RELEASE COMPOSITION RESISTANT TO ABUSE BY INTAKE OF ALCOHOL | EGALET LTD. (GB) | 2015-11-05 | — | — | US | disclosed |
| US-20150306040-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2015-10-29 | — | — | US | disclosed |
| US-9168228-B2 | Pharmaceutical compositions resistant to abuse | EGALET LTD. (GB) | 2015-10-27 | — | — | US | disclosed |
| US-20150297525-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2015-10-22 | — | — | US | disclosed |
| WO-2015157150-A1 | OPIOID ABUSE-DETERRENT CONTROLLED RELEASE FORMULATIONS | BANNER LIFE SCIENCES LLC (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150290211-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2015-10-15 | — | — | US | disclosed |
| WO-2015157138-A1 | ABUSE-DETERRENT CONTROLLED RELEASE FORMULATIONS | BANNER LIFE SCIENCES LLC (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150283087-A1 | ABUSE-DETERRENT CONTROLLED RELEASE FORMULATIONS | PATHEON SOFTGELS INC. | 2015-10-08 | — | — | US | disclosed |
| US-20150283088-A1 | OPIOID ABUSE-DETERRENT CONTROLLED RELEASE FORMULATIONS | PATHEON SOFTGELS INC. | 2015-10-08 | — | — | US | disclosed |
| US-9151749-B2 | Assay device comprising bubble-forming means | ALERE SWITZERLAND GMBH (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20150204893-A1 | TEST KIT FOR THE QUANTITATIVE DETERMINATION OF NARCOTIC DRUGS | CHIRON AS (NO) | 2015-07-23 | — | — | US | disclosed |
| US-20150150812-A1 | CONTROLLED RELEASE FORMULATIONS WITH CONTINUOUS EFFICACY | EGALET LTD. (GB) | 2015-06-04 | — | — | US | disclosed |
| US-20150152348-A1 | SYSTEMS AND METHODS FOR COLLECTING, TRANSPORTING AND REPURPOSING OR DESTROYING UNUSED PHARMACEUTICALS | SHARPS COMPLIANCE, INC. OF TEXAS | 2015-06-04 | — | — | US | disclosed |
| EP-2877161-A1 | ABUSE DETERRENT PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED RELEASE | Egalet Ltd. (GB) | 2015-06-03 | — | — | EP | disclosed |
| US-9044402-B2 | Abuse-deterrent pharmaceutical compositions for controlled release | EGALET LTD. (GB) | 2015-06-02 | — | — | US | disclosed |
| EP-2875362-A1 | TEST KIT FOR THE QUANTITATIVE DETERMINATION OF NARCOTIC DRUGS | Chiron AS (NO) | 2015-05-27 | — | — | EP | disclosed |
| US-9023394-B2 | Formulations and methods for the controlled release of active drug substances | EGALET LTD. (GB) | 2015-05-05 | — | — | US | disclosed |
| US-9005660-B2 | Immediate release composition resistant to abuse by intake of alcohol | EGALET LTD. (GB) | 2015-04-14 | — | — | US | disclosed |
| US-20150025063-A1 | Antiparkinsonian Action of Phenylisopropylamines | UNIV DUKE (US) | 2015-01-22 | — | — | US | disclosed |
| WO-2014195785-A1 | IMPROVED DATA QUALITY AFTER DEMULTIPLEXING OF OVERLAPPING ACQUISITION WINDOWS | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2014-12-11 | — | — | WO | disclosed |
| US-8877802-B2 | Antiparkinsonian action of phenylisopropylamines | Duke Univerity (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140308349-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2014153099-A2 | METHOD FOR USING EXHALED BREATH TO DETERMINE THE PRESENCE OF DRUG | Pulmonary Analytics (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140288454-A1 | Method For Using Exhaled Breath to Determine the Presence of Drug | Pulmonary Analytics (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140227792-A1 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | CHIRON A/S (NO) | 2014-08-14 | — | — | US | disclosed |
| US-20140220126-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED RELEASE | EGALET LTD. (GB) | 2014-08-07 | — | — | US | disclosed |
| US-8728522-B2 | Pharmaceutical compositions for treating or preventing pain | CHARLESTON LABORATORIES, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2700400-A1 | Controlled release formulation with continuous efficacy | Egalet Ltd. (GB) | 2014-02-26 | — | — | EP | disclosed |
| US-20140050787-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | EGALET LTD. (GB) | 2014-02-20 | — | — | US | disclosed |
| US-20140030322-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2014-01-30 | — | — | US | disclosed |
| WO-2014013063-A1 | TEST KIT FOR THE QUANTITATIVE DETERMINATION OF NARCOTIC DRUGS | CHIRON AS (NO) | 2014-01-23 | — | — | WO | disclosed |
| EP-2687854-A1 | Test kit for the quantitative determination of narcotic drugs | Chiron AS (NO) | 2014-01-22 | — | — | EP | disclosed |
| WO-2014006004-A1 | ABUSE DETERRENT PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED RELEASE | EGALET LTD. (GB) | 2014-01-09 | — | — | WO | disclosed |
| US-8603526-B2 | Pharmaceutical compositions resistant to abuse | EGALET LTD. (GB) | 2013-12-10 | — | — | US | disclosed |
| US-20130287849-A1 | FORMULATIONS AND METHODS FOR THE CONTROLLED RELEASE OF ACTIVE DRUG SUBSTANCES | ZYLA LIFE SCIENCES US INC., F/K/A EGALET US, INC. | 2013-10-31 | — | — | US | disclosed |
| US-20130287850-A1 | FORMULATIONS AND METHODS FOR THE CONTROLLED RELEASE OF ACTIVE DRUG SUBSTANCES | ZYLA LIFE SCIENCES US INC., F/K/A EGALET US, INC. | 2013-10-31 | — | — | US | disclosed |
| US-8563038-B2 | Formulations and methods for the controlled release of active drug substances | EGALET LTD. (GB) | 2013-10-22 | — | — | US | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| WO-2013103841-A1 | METHODS FOR QUANTITATIVE CHIRAL DETERMINATION OF THE d- AND l- ENANTIOMERS OF AMPHETAMINE AND METHAMPHETAMINE | CLINICAL REFERENCE LABORATORY, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130177994-A1 | METHODS FOR QUANTITATIVE CHIRAL DETERMINATION OF THE d- AND l- ENANTIOMERS OF AMPHETAMINE AND METHAMPHETAMINE | CLINICAL REFERENCE LABORATORY, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8440706-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| WO-2013014287-A2 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | CHIRON AS (NO) | 2013-01-31 | — | — | WO | disclosed |
| EP-2551675-A1 | Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods fo their preparation and their use | Chiron AS (NO) | 2013-01-30 | — | — | EP | disclosed |
| EP-1828106-B1 | METHAMPHETAMINE DERIVATIVES AND CONJUGATES FOR IMMUNOASSAY | ROCHE DIAGNOSTICS GMBH (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20120201888-A1 | Pharmaceutical Compositions | CHARLESTON LABORATORIES, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| EP-2451274-A1 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2445487-A2 | CONTROLLED RELEASE FORMULATIONS | Egalet Ltd. (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-8124126-B2 | Pharmaceutical compositions | CHARLESTON LABORATORIES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2389169-A1 | CONTROLLED RELEASE FORMULATIONS WITH CONTINUOUS EFFICACY | Egalet A/S (DK) | 2011-11-30 | — | — | EP | disclosed |
| US-20110262539-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-1917269-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2011-10-26 | — | — | EP | disclosed |
| US-8038094-B2 | Hydraulic system for aircraft | HONDA MOTOR CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110159100-A1 | FORMULATIONS AND METHODS FOR THE CONTROLLED RELEASE OF ACTIVE DRUG SUBSTANCES | EGALET A/S (DK) | 2011-06-30 | — | — | US | disclosed |
| WO-2011006012-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010149169-A2 | CONTROLLED RELEASE FORMULATIONS | EGALET A/S (DK) | 2010-12-29 | — | — | WO | disclosed |
| US-20100291205-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR MITIGATING RISK OF ALCOHOL INDUCED DOSE DUMPING OR DRUG ABUSE | EGALET A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| EP-2240022-A2 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010088911-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | EGALET A/S (DK) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010089132-A1 | IMMEDIATE RELEASE COMPOSITION RESISTANT TO ABUSE BY INTAKE OF ALCOHOL | EGALET A/S (DK) | 2010-08-12 | — | — | WO | disclosed |
| US-20100203130-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | EGALET A/S (DK) | 2010-08-12 | — | — | US | disclosed |
| US-20100203129-A1 | CONTROLLED RELEASE FORMULATIONS WITH CONTINUOUS EFFICACY | EGALET A/S (DK) | 2010-08-12 | — | — | US | disclosed |
| US-20100204259-A1 | IMMEDIATE RELEASE COMPOSITION RESISTANT TO ABUSE BY INTAKE OF ALCOHOL | EGALET A/S (DK) | 2010-08-12 | — | — | US | disclosed |
| WO-2010083843-A1 | CONTROLLED RELEASE FORMULATIONS WITH CONTINUOUS EFFICACY | EGALET A/S (DK) | 2010-07-29 | — | — | WO | disclosed |
| US-20100140160-A1 | Nanofiber surface for use in enhanced surfaces area appications | NANOSYS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7732160-B2 | Methamphetamine derivatives and conjugates for immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20090311696-A1 | POLYMORPHISMS IN THE HUMAN CYP2B6 GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | EPIDAUROS BIOTECHNOLOGIE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| EP-2104493-A2 | USE OF I) A POLYGLYCOL AND N) AN ACTIVE DRUG SUBSTANCE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR I) MITIGATING THE RISK OF ALCOHOL INDUCED DOSE DUMPING AND/OR II) REDUCING THE RISK OF DRUG ABUSE | Egalet A/S (DK) | 2009-09-30 | — | — | EP | disclosed |
| US-7579077-B2 | Suppression of biofilm production; semiconductors | NANOSYS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| WO-2009089494-A2 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090175939-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080207601-A1 | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence | HYTHIAM , INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008086804-A2 | USE OF I) A POLYGLYCOL AND N) AN ACTIVE DRUG SUBSTANCE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR I) MITIGATING THE RISK OF ALCOHOL INDUCED DOSE DUMPING AND/OR II) REDUCING THE RISK OF DRUG ABUSE | EGALET A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| US-20080075772-A1 | PHARMACEUTICAL COMPOSITIONS HAVING NOVEL SCORING PATTERNS AND METHODS OF USING THOSE COMPOSITIONS | ACCU-BREAK TECHNOLOGIES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080050843-A1 | METHAMPHETAMINE DERIVATIVES AND CONJUGATES FOR IMMUNOASSAY | HUI RAYMOND A | 2008-02-28 | — | — | US | disclosed |
| WO-2008003044-A2 | METHOD AND APPARATUS FOR HUMAN BEHAVIORAL MONITORING | THE REGENTS OF UNIVERSITY OF CALIFORNIA (US) | 2008-01-03 | — | — | WO | disclosed |
| EP-0983514-B1 | A PROCESS AND A TEST KIT FOR HEROIN DETECTION | IDENTA LTD (IL) | 2007-12-19 | — | — | EP | disclosed |
| US-7294649-B2 | Methamphetamine derivatives and conjugates for immunoassay | ROCHE DIAGNOSTICS OPERATINS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1828106-A2 | METHAMPHETAMINE DERIVATIVES AND CONJUGATES FOR IMMUNOASSAY | Roche Diagnostics GmbH (DE) | 2007-09-05 | — | — | EP | disclosed |
| US-20070148660-A1 | Treatment of maladaptive substance use with H-ras antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-06-28 | — | — | US | disclosed |
| WO-2007069925-A2 | NON-NEUROTOXIC RECREATIONAL DRUGS AND A METHOD OF TREATING RECREATIONAL DRUG ABUSE | STARGATE INTERNATIONAL LIMITED (NZ) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007063326-A2 | ASSAY DEVICE AND METHOD | INVERNESS MEDICAL SWITZERLAND GMBH (CH) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
| US-7169907-B2 | Derivatives, immunogens, and antibodies for detecting ecstasy-class drugs | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20060258647-A1 | Treatment of maladaptive substance use with cholecystokinin (CCK) antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-11-16 | — | — | US | disclosed |
| US-7101980-B2 | Derivatives, conjugates, and antibodies for detecting ecstasy-class analytes | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060178307-A1 | Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-08-10 | — | — | US | disclosed |
| WO-2006081522-A2 | MODULATION OF NMDA RECEPTOR CURRENTS VIA OREXIN RECEPTOR AND/OR CRF RECEPTOR | THE REGENTS OF THE UNVERSITY OF CALIFORNIA (US) | 2006-08-03 | — | — | WO | disclosed |
| US-20060159916-A1 | Suppression of biofilm production; semiconductors | NANOSYS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| US-7078406-B2 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20060134711-A1 | Methamphetamine derivatives and conjugates for immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006063829-A2 | METHAMPHETAMINE DERIVATIVES AND CONJUGATES FOR IMMUNOASSAY | ROCHE DIAGNOSTICS GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
| EP-1620256-A2 | NANOFIBER SURFACES FOR USE IN ENHANCED SURFACE AREA APPLICATIONS | Nanosys, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-6946547-B2 | Ecstasy-class analogs and use of same in detection of ecstasy-class compounds | MICROGENICS CORPORATION (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1498428-A1 | Antibodies for detecting ecstasy-class analytes | Roche Diagnostics GmbH (DE) | 2005-01-19 | — | — | EP | disclosed |
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | Life Technologies Corporation | 2004-12-09 | — | — | US | disclosed |
| WO-2004099068-A2 | NANOFIBER SURFACES FOR USE IN ENHANCED SURFACE AREA APPLICATIONS | NANOSYS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040224313-A1 | Comprises nucleotide sequences coding cytochrome p450 oxygenase variant for identifying modulator use in diagnosis, prognosis, treatment and prevention of cell proliferative disorders; antitumor agents | TRANSGENOMIC, INC. | 2004-11-11 | — | — | US | disclosed |
| US-6815445-B2 | FOR USE AS FLUORESCENCE DYES AND PROBES | Life Technologies Corporation | 2004-11-09 | — | — | US | disclosed |
| US-20040077021-A1 | Derivatives, conjugates, and antibodies for detecting ecstasy-class analytes | ROCHE DIAGNOSTICS CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20030224435-A1 | Detection of abused substances and their metabolites using nucleic acid sensor molecules | SIRNA THERAPEUTICS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030207469-A1 | Ecstasy-class analogs and use of same in detection of ecstasy-class compounds | MICROGENICS CORPORATION (US) | 2003-11-06 | — | — | US | disclosed |
| US-20030175995-A1 | Compounds, antibodies, reagent kits, methods of producing antibodies, and methods of detecting analytes | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2003-09-18 | — | — | US | disclosed |
| EP-1340981-A2 | Antibodies for detecting amphetamine derivatives | Roche Diagnostics GmbH (DE) | 2003-09-03 | — | — | EP | disclosed |
| EP-1340980-A1 | Derivatives of amphetamine, antibodies against said derivatives, reagent kits, methods of producing said antibodies, and methods of detecting said derivatives | Roche Diagnostics GmbH (DE) | 2003-09-03 | — | — | EP | disclosed |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| EP-1272663-A2 | POLYMORPHISMS IN THE HUMAN CYP2B6 GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Epidauros Biotechnologie AG (DE) | 2003-01-08 | — | — | EP | disclosed |
| US-6472227-B1 | A FLUORESCEIN MOIETY IS INCLUDED IN THE TRACER, WHILE A POLY(AMINO ACID) FORMS A PART OF THE IMMUNOGEN FOR DETERMINING THE AMOUNT OF BARBITURATE IN FLUIDS, ESPECIALLY BIOLOGICAL FLUIDS SUCH AS SERUM, PLASMA OR URINE | ABBOTT LABORATORIES | 2002-10-29 | — | — | US | disclosed |
| WO-2001059152-A9 | POLYMORPHISMS IN THE HUMAN CYP2B6 GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | EPIDAUROS BIOTECHNOLOGIE AG (DE) | 2002-08-08 | — | — | WO | disclosed |
| WO-2001059152-A2 | POLYMORPHISMS IN THE HUMAN CYP2B6 GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | EPIDAUROS BIOTECHNOLOGIE AG (DE) | 2001-08-16 | — | — | WO | disclosed |
| EP-0983514-A1 | A PROCESS AND A TEST KIT FOR HEROIN DETECTION | Identa Ltd. (IL) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998045714-A1 | A PROCESS AND A TEST KIT FOR HEROIN DETECTION | IDENTA LTD. (IL) | 1998-10-15 | — | — | WO | disclosed |
| EP-0399184-B1 | Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassay | ABBOTT LAB (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5354693-A | Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassy | ABBOTT LABORATORIES (US) | 1994-10-11 | — | — | US | disclosed |
| US-5248791-A | Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassay | ABBOTT LABORATORIES (US) | 1993-09-28 | — | — | US | disclosed |
| US-5155212-A | Substituted phencyclidine compound linked to polyamino acid | ABBOTT LABORATORIES (US) | 1992-10-13 | — | — | US | disclosed |
| US-5101015-A | Nitrogen-functional-group-containing immunogen | ABBOTT LABORATORIES (US) | 1992-03-31 | — | — | US | disclosed |
| EP-0399184-A2 | Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassay | ABBOTT LABORATORIES (US) | 1990-11-28 | — | — | EP | disclosed |
| EP-0399184-A2 | Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassay | ABBOTT LABORATORIES (US) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220126-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED RELEASE | OPRK1, OPRM1, OPRL1 | SIGMAR1 4/4885SLC6A4 85/4885LMNA 4345/4885 |
| US-11123310-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | SIGMAR1 80/4885SLC6A4 6/4885LMNA 4869/4885 |
| US-20260078090-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | HTR1D, TPH1, HTR3D | SIGMAR1 104/4885SLC6A4 12/4885LMNA 4495/4885 |
| US-20250129037-A1 | FLUORINATED EMPATHOGENS | SLC18A2, BDNF, GAP43 | SIGMAR1 185/4885SLC6A4 11/4885LMNA 2726/4885 |
| US-12180176-B2 | Fluorinated empathogens | SLC18A2, BDNF, GAP43 | SIGMAR1 185/4885SLC6A4 11/4885LMNA 2726/4885 |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | SLC6A3, SLC6A2, CES2 | SIGMAR1 78/4885SLC6A4 4/4885LMNA 4850/4885 |
| US-20140227792-A1 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | PNMT, HTR2C, HTR2A | SIGMAR1 66/4885SLC6A4 50/4885LMNA 541/4885 |
| US-11767305-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | BDNF, CREBBP, ELF3 | SIGMAR1 4113/4885SLC6A4 457/4885LMNA 3750/4885 |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | SLC6A3, CREBBP, SLC1A2 | SIGMAR1 3275/4885SLC6A4 21/4885LMNA 4660/4885 |
| US-20230150963-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | BDNF, CREBBP, ELF3 | SIGMAR1 4113/4885SLC6A4 457/4885LMNA 3750/4885 |
| US-20240285606-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, BDNF, HTR6 | SIGMAR1 421/4885SLC6A4 90/4885LMNA 3258/4885 |
| US-12239632-B2 | Asymmetric allyl tryptamines | TPH2, TPH1, HTR2A | SIGMAR1 200/4885SLC6A4 21/4885LMNA 2872/4885 |
| US-12454515-B2 | 2-aminoindane compounds for mental disorders or enhancement | AADAT, SLC1A2, TPH2 | SIGMAR1 3691/4885SLC6A4 153/4885LMNA 2860/4885 |
| US-20140050787-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | OPRK1, CES2, OPRM1 | SIGMAR1 8/4885SLC6A4 85/4885LMNA 3039/4885 |
| US-20110159100-A1 | FORMULATIONS AND METHODS FOR THE CONTROLLED RELEASE OF ACTIVE DRUG SUBSTANCES | SLC18A1, CRH, NPSR1 | SIGMAR1 134/4885SLC6A4 47/4885LMNA 1294/4885 |
| US-11660305-B2 | Tryptamine compositions for enhancing neurite outgrowth | HTR1B, HTR6, BDNF | SIGMAR1 449/4885SLC6A4 62/4885LMNA 3255/4885 |
| US-12404257-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | BDNF, CREBBP, ELF3 | SIGMAR1 4113/4885SLC6A4 457/4885LMNA 3750/4885 |
| US-11851452-B2 | Psilocybin and O-acetylpsilocin, salts and solid state forms thereof | AANAT, PSAP, SPTSSB | SIGMAR1 3224/4885SLC6A4 112/4885LMNA 3079/4885 |
| US-12577222-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | DRD2, DRD1, DRD3 | SIGMAR1 89/4885SLC6A4 59/4885LMNA 2800/4885 |
| US-20240000795-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | HTR2A, HTR1A, HTR2C | SIGMAR1 150/4885SLC6A4 24/4885LMNA 1388/4885 |
| US-20230257385-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | SLC6A2, SLC6A4, SLC6A3 | SIGMAR1 2001/4885SLC6A4 2/4885LMNA 4611/4885 |
| US-20240082274-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | MAOB, TPSG1, TPSB2 | SIGMAR1 1227/4885SLC6A4 1378/4885LMNA 2192/4885 |
| US-20240358783-A1 | METHOD AND SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF A PSYCHEDELIC AGENT | HTR7, HTR6, PNMT | SIGMAR1 373/4885SLC6A4 17/4885LMNA 1549/4885 |
| US-20240083864-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | BDNF, CREBBP, ELF3 | SIGMAR1 4113/4885SLC6A4 457/4885LMNA 3750/4885 |
| US-20210251976-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | SIGMAR1 449/4885SLC6A4 62/4885LMNA 3255/4885 |
| US-20150150812-A1 | CONTROLLED RELEASE FORMULATIONS WITH CONTINUOUS EFFICACY | ABCB11, CRH, LPXN | SIGMAR1 147/4885SLC6A4 245/4885LMNA 3629/4885 |
| US-20240409526-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | DRD2, DRD3, DRD1 | SIGMAR1 369/4885SLC6A4 16/4885LMNA 4105/4885 |
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | HTR1D, HTR2C, TPH1 | SIGMAR1 140/4885SLC6A4 15/4885LMNA 4144/4885 |
| US-20260138985-A1 | Azepino-Indoles for the Treatment of Neurological and Psychiatric Disorders | TPH2, TPH1, HTR1D | SIGMAR1 1075/4885SLC6A4 28/4885LMNA 3893/4885 |
| US-20160074332-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | OPRK1, CES2, OPRM1 | SIGMAR1 8/4885SLC6A4 85/4885LMNA 3039/4885 |
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | CNR2, CNR1, HCN3 | SIGMAR1 62/4885SLC6A4 54/4885LMNA 1574/4885 |
| US-12612364-B2 | Salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine hemi-glutarate and hemi-succinate | SLC6A4, DLST, GRIN2D | SIGMAR1 690/4885SLC6A4 1/4885LMNA 2949/4885 |
| US-20260021069-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | HCN1, HCN4, CRH | SIGMAR1 821/4885SLC6A4 20/4885LMNA 4146/4885 |
| US-11896587-B2 | Tryptamine compositions for enhancing neurite outgrowth | HTR1B, HTR6, BDNF | SIGMAR1 449/4885SLC6A4 62/4885LMNA 3255/4885 |
| US-20100203130-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | OPRK1, CES2, OPRM1 | SIGMAR1 8/4885SLC6A4 85/4885LMNA 3039/4885 |
| US-20250179042-A1 | USE OF DEUTERATED EMPATHOGENS AS THERAPEUTIC AGENTS | SLC18A2, SLC6A3, GAP43 | SIGMAR1 439/4885SLC6A4 18/4885LMNA 3775/4885 |
| US-20240342126-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | FAAH, HTR5A, FAAH2 | SIGMAR1 195/4885SLC6A4 44/4885LMNA 990/4885 |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | SIGMAR1 188/4885SLC6A4 178/4885LMNA 2266/4885 |
| US-12234216-B2 | Isotopologues salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof | PYGB, NR3C2, CYP11B1 | SIGMAR1 1237/4885SLC6A4 22/4885LMNA 2163/4885 |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | SIGMAR1 449/4885SLC6A4 62/4885LMNA 3255/4885 |
| US-20250195471-A1 | ASYMMETRIC ALLYL TRYPTAMINES | TPH2, TPH1, HTR2A | SIGMAR1 200/4885SLC6A4 21/4885LMNA 2872/4885 |
| US-20240277691-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, BDNF, HTR6 | SIGMAR1 421/4885SLC6A4 90/4885LMNA 3258/4885 |
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | DHFR, FPR1, CYP1A1 | SIGMAR1 1287/4885SLC6A4 3578/4885LMNA 1981/4885 |
| US-11878001-B2 | Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use | CES2, CSGALNACT1, SLC6A3 | SIGMAR1 517/4885SLC6A4 5/4885LMNA 4224/4885 |
| US-20230183199-A1 | 2-AMINOINDANE COMPOUNDS FOR MENTAL DISORDERS OR ENHANCEMENT | AADAT, SLC1A2, TPH2 | SIGMAR1 3691/4885SLC6A4 153/4885LMNA 2860/4885 |
| US-20240285578-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | MAOA, MAOB, HTR1A | SIGMAR1 92/4885SLC6A4 110/4885LMNA 3017/4885 |
| US-20240285607-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, BDNF, HTR6 | SIGMAR1 421/4885SLC6A4 90/4885LMNA 3258/4885 |
| US-20030207469-A1 | Ecstasy-class analogs and use of same in detection of ecstasy-class compounds | CES2, DNPEP, HLA-A | SIGMAR1 353/4885SLC6A4 208/4885LMNA 4198/4885 |
| US-20230150966-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | SLC6A3, DBH, PNMT | SIGMAR1 139/4885SLC6A4 12/4885LMNA 4268/4885 |
| US-12465578-B2 | Substituted alpha-ethyl phenylalkylamines | PNMT, SLC18A2, SLC1A2 | SIGMAR1 66/4885SLC6A4 10/4885LMNA 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.